SEC Form 4 · accession 0001171843-15-004814
Xenon Pharmaceuticals Inc. · XENE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank A Holler
Director
Period of report
Aug 18, 2015
Accepted (ET)
Aug 20, 2015 · 1:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001582313
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Aug 18, 2015 | M | 2,057 | $4.98 | A | 175,675 | D | |
| Common SharesF2 | Aug 18, 2015 | F | 868 | $11.00 | D | 174,807 | D | |
| Common Shares | holding | — | — | — | 1,184 | I | By spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F3 | $4.98 | Aug 18, 2015 | M | 2,057 | D | — | Aug 24, 2015 | Common Shares | 2,057 | 0 | D |
Explanation of responses
- F1The exercise price was converted from $6.07 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- F2Represents the closing price of the Company's common shares on August 17, 2015, converted to a Canadian dollar amount for purposes of net settlement calculations.
- F3The shares subject to the option fully vested on January 1, 2008.